Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 215

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Q1 2026 Psychedelic Patent Update

The Psychedelic Practitioner Issue 4: Integration

Shane Mauss – Comedy and Molecules – Episode 14

March 2026 Psychedelic Bill Round-up

Ketamine-Assisted Couple Therapy Training by Enamory

Psychedelic Bulletin: DEA Again Increases Psychedelics Production Quotas; MindMed Announces Microdosing...

Numinus to Begin Trading on the OTC Under Symbol NUMIF

Tryp Therapeutics Provides Update on Clinical Hold for Phase 2a Study...

PTSF85 – Ahmad Doroudian, Ph.D. of BetterLife Pharma and Dr. Abid...

Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human...

Wesana Health Clinics Surpass 4,000 Administered Ketamine Treatments

MYND Diagnostics Commences Clinical Research on Multiple Sclerosis Biomarker Test

Small Pharma Strengthens Board With Appointment of Paul Maier as Independent...

Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for...

Eyes on Oregon, a Psychedelics Today Podcast with Jon Dennis and...

Load more

EDITOR PICKS

Q1 2026 Psychedelic Patent Update

The Psychedelic Practitioner Issue 4: Integration

Shane Mauss – Comedy and Molecules – Episode 14

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©